Characteristics of analyzed patients at ruxolitinib start
| Features . | Low risk (N = 10) . | Intermediate risk (N = 92) . | High risk (N = 38) . | P . |
|---|---|---|---|---|
| Sex (%) | .98 | |||
| Male, n | 5 (3.6) | 49 (35) | 20 (14.3) | |
| Female, n | 5 (3.6) | 43 (30.7) | 18 (12.9) | |
| Age at diagnosis, median, y (range) | 54 (32-84) | 64 (16-82) | 62.5 (38-81) | .15 |
| Primary MF, n (%) | 3 (2.1) | 42 (30) | 20 (14.3) | .29 |
| Post–polycythemia vera, n (%) | 4 (2.9) | 26 (18.6) | 5 (3.6) | |
| Post–essential thrombocythemia, n (%) | 3 (2.1) | 24 (17.1) | 13 (9.3) | |
| Early MF, n (%) | 2 (1.4) | 14 (10.1) | 3 (2.2) | |
| Overt MF (%) | 8 (5.8) | 78 (56.5) | 35 (23.9) | |
| Grade of fibrosis (%) | .50 | |||
| 0 to 1, n | 2 (1.4) | 13 (9.3) | 6 (4.3) | |
| 2, n | 4 (2.9) | 36 (25.9) | 12 (8.6) | |
| 3, n | 4 (2.9) | 43 (30.9) | 20 (13.7) | |
| IPSS | ||||
| Low | 2 | 5 | 1 | |
| Int-1 | 1 | 12 | 4 | .24 |
| Int-2 | —* | 20 | 9 | |
| High | — | 5 | 6 | |
| MYSEC-PM | ||||
| Low | 1 | 5 | — | |
| Int-1 | 5 | 15 | 2 | .35 |
| Int-2 | 1 | 22 | 13 | |
| High | — | 8 | 3 | |
| Symptoms at diagnosis, n (%) | 3 (2.1) | 42 (30) | 13 (9.3) | .36 |
| JAK2 mutated, n (%) | 6 (4.3) | 67 (47.9) | 25 (17.9) | .56 |
| CALR mutated, n (%) | 1 (0.7) | 8 (5.7) | 6 (4.3) | .46 |
| TTS, median (range) | 0 (0-55) | 10 (0-70) | 15 (0-50) | .35 |
| Transfusion dependent, n (%) | /* | 23 (16.5) | 21 (15.1) | .42 |
| Palpable spleen below LCM, median, cm (range) | 5.5 (0-15) | 6 (0-23) | 4.5 (0-16) | .015 |
| Dose at ruxolitinib start (%) | .013 | |||
| 5 mg bid, n | / | 10 (7.2) | 5 (3.6) | |
| 10 mg bid, n | / | 20 (14.5) | 7 (5.1) | |
| 15 mg bid, n | / | 28 (20.3) | 11 (7.2) | |
| 20 mg bid, n | 10 (7.2) | 34 (23.9) | 15 (10.9) | |
| Features . | Low risk (N = 10) . | Intermediate risk (N = 92) . | High risk (N = 38) . | P . |
|---|---|---|---|---|
| Sex (%) | .98 | |||
| Male, n | 5 (3.6) | 49 (35) | 20 (14.3) | |
| Female, n | 5 (3.6) | 43 (30.7) | 18 (12.9) | |
| Age at diagnosis, median, y (range) | 54 (32-84) | 64 (16-82) | 62.5 (38-81) | .15 |
| Primary MF, n (%) | 3 (2.1) | 42 (30) | 20 (14.3) | .29 |
| Post–polycythemia vera, n (%) | 4 (2.9) | 26 (18.6) | 5 (3.6) | |
| Post–essential thrombocythemia, n (%) | 3 (2.1) | 24 (17.1) | 13 (9.3) | |
| Early MF, n (%) | 2 (1.4) | 14 (10.1) | 3 (2.2) | |
| Overt MF (%) | 8 (5.8) | 78 (56.5) | 35 (23.9) | |
| Grade of fibrosis (%) | .50 | |||
| 0 to 1, n | 2 (1.4) | 13 (9.3) | 6 (4.3) | |
| 2, n | 4 (2.9) | 36 (25.9) | 12 (8.6) | |
| 3, n | 4 (2.9) | 43 (30.9) | 20 (13.7) | |
| IPSS | ||||
| Low | 2 | 5 | 1 | |
| Int-1 | 1 | 12 | 4 | .24 |
| Int-2 | —* | 20 | 9 | |
| High | — | 5 | 6 | |
| MYSEC-PM | ||||
| Low | 1 | 5 | — | |
| Int-1 | 5 | 15 | 2 | .35 |
| Int-2 | 1 | 22 | 13 | |
| High | — | 8 | 3 | |
| Symptoms at diagnosis, n (%) | 3 (2.1) | 42 (30) | 13 (9.3) | .36 |
| JAK2 mutated, n (%) | 6 (4.3) | 67 (47.9) | 25 (17.9) | .56 |
| CALR mutated, n (%) | 1 (0.7) | 8 (5.7) | 6 (4.3) | .46 |
| TTS, median (range) | 0 (0-55) | 10 (0-70) | 15 (0-50) | .35 |
| Transfusion dependent, n (%) | /* | 23 (16.5) | 21 (15.1) | .42 |
| Palpable spleen below LCM, median, cm (range) | 5.5 (0-15) | 6 (0-23) | 4.5 (0-16) | .015 |
| Dose at ruxolitinib start (%) | .013 | |||
| 5 mg bid, n | / | 10 (7.2) | 5 (3.6) | |
| 10 mg bid, n | / | 20 (14.5) | 7 (5.1) | |
| 15 mg bid, n | / | 28 (20.3) | 11 (7.2) | |
| 20 mg bid, n | 10 (7.2) | 34 (23.9) | 15 (10.9) | |
indicates zero.
bid, twice daily; CALR, calreticulin; JAK2, Januse Kinase 2; LCM, low costal margin; TTS, total symptom score.